Radiopharm Theranostics Ltd. has been granted Belberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I therapeutic study of 177Lu-labeled RAD-202 ...

The phase 1 first-in-human study is designed to assess the safety, tolerability & preliminary clinical activity of 177Lu-RAD202 in individuals with HER2-positive metastatic solid tumours. The ...

Phase 1 therapeutic clinical study of 177Lu-labelled RAD 202 for the treatment of HER2-expressing solid tumors. The open-label Phase 1 trial, entitled ‘HEAT’ (HER2 Antibody Therapy with Lutetium-177), ...

EQS-News: Eckert & Ziegler SE / Key word (s): Alliance/Incoming Orders Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement 13.01.2025 / 10:00 CET/CEST The issuer ...

The main function of RAD204 – a single domain monoclonal antibody – is its targeting ... supporting the potential of 177Lu-RAD204 for a tumor-agnostic indication and as an effective ...